Media no image

​Athera startar klinisk studie inom arteriell inflammation med antikroppen PC-mAb

Press Releases   •   Oct 11, 2017 09:01 CEST

Stockholm 11 oktober, 2017 Athera Biotechnologies AB meddelar idag att screening har startats i den prospektiva, dubbelblindade, randomiserade, placebo-kontrollerade Phase 2a studien med PC-mAb inom arteriell inflammation. Studiepopulationen är personer med förhöjda nivåer av lipoprotein a, förkortat Lp(a), en lipidpartikel i blodet som har hög kapacitet att bära phosphorylcholine, PC, som är den pro-inflammatoriska målstrukturen som PC-mAb binder till.

Professor Erik Stroes på avdelningen för Vascular Medicine på AMC Amsterdam Medical Center är Principal Investigator i studien. “Vi är mycket glada för att studien med PC-mAb nu startats” säger Professor Stroes. “Studien är väl positionerad i den våg av nya behandlingar som förväntas utvecklas inom det inflammatoriska området efter de positiva resultat som nyligen presenterats i den stora CANTOS studien, som riktade behandling mot den risk för hjärt-kärlsjukdom som orsakas av inflammationskomponenten vid åderförkalkningssjukdom.”

“Vår fullt humana antikropp PC-mAb har designats med egenskaper som imiterar den anti-inflammatoriska roll som de kroppsegna antikropparna mot PC har, och som därför kan agera som stöd för immunförsvaret mot vaskulär inflammation och därigenom minska risken för hjärt-kärlkomplikationer” säger Professor Gunnar Olsson, styrelseordförande i Athera. “Vi är mycket nöjda med att ha nått den här milstolpen och ser fram emot att samarbeta med gruppen på AMC som är världsledande inom klinisk forskning kring vaskulär inflammation.”

Det primära målet med studien är att undersöka effekten av månatliga intravenösa injektioner av PC-mAb på monocyters funktion vid ex vivo testning av dessa celler. Studien avser även att undersöka funktionella effekter på arteriell inflammation in vivo samt artärväggarnas styvhet. Säkerhet och tolererbarhet av PC-mAb behandlingen kommer också att följas. Studien genomförs på två kliniker; dels på AMC Amsterdam Medical Center i Nederländerna, dels på CTC Clinical Trials Consultants i Uppsala, i Sverige.

För mera information, kontakta: Carina Schmidt, CEO, Athera Biotechnologies AB Telefon: +46 (0)76 1938 190, email: c.schmidt@athera.se

Om Athera Biotechnologies AB

Athera är ett innovativt bioteknikbolag med visionen att bidra till bättre behandlingar inom kärlsjukdomar, där det finns ett stort medicinskt behov att adressera den inflammatoriska risken. Bolaget utvecklar biologiska läkemedel, som riktar in sig mot den inflammatoriska komponenten i kärlsjukdomar, genom att agera som stöd för immunförsvaret. Fokus i utveckling läggs på den terapeutiska antikroppen PC-mAb. Största ägare i bolaget är Industrifonden, Östersjöstiftelsen och Linc AB. För mera information besök www.athera.se

Athera meddelar idag att screening har startats i en Phase 2a studie med PC-mAb inom arteriell inflammation. Studiepopulationen är personer med förhöjda nivåer av lipoprotein a, förkortat Lp(a), en lipidpartikel i blodet som har hög kapacitet att bära phosphorylcholine, PC, som är den pro-inflammatoriska målstrukturen som PC-mAb binder till.

Read more »
Media no image

​Athera initiates Phase 2a trial on arterial inflammation with its antibody PC-mAb

Press Releases   •   Oct 11, 2017 09:00 CEST

Stockholm October 11, 2017 Athera Biotechnologies AB today announced that screening has started for a Phase 2a prospective, double-blind, randomised, placebo-controlled multicentre study to investigate the effects of treatment on arterial inflammation with PC-mAb. The study population consists of individuals with elevated levels of lipoprotein a or Lp(a), a plasma lipoprotein with high capacity to carry phosphorylcholine, PC, the pro-inflammatory target for PC-mAb.

Professor Erik Stroes of Department of Vascular Medicine at AMC Amsterdam Medical Center is Principal Investigator of the study. “We are pleased to initiate this study with PC-mAb” says Professor Stroes. “This study is very well positioned in the expected wave of new therapy developments in the inflammatory field, following the recent positive results from the large CANTOS study which was targeting the residual risk after cardiovascular events, caused by inflammation.”

“Our fully human antibody PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications” says Professor Gunnar Olsson, Chairman of the Board of Athera. “We are happy to have reached this important milestone and look forward to working with the cutting-edge science group at AMC in this study.”

The primary objective of the study is to assess the effects of PC-mAb dosing with once monthly intravenous injections on monocyte function by ex vivo testing of these cells. Secondarily the study aims to assess the functional effects on arterial inflammation in vivo and on arterial wall stiffness, as well as safety and tolerability of PC-mAb. The study sites include AMC Amsterdam Medical Center, the Netherlands, and CTC Clinical Trials Consultants in Uppsala, Sweden.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Athera today announced that screening has started for a Phase 2a study to investigate the effects of treatment on arterial inflammation with PC-mAb. The study population consists of individuals with elevated levels of lipoprotein a or Lp(a), a plasma lipoprotein with high capacity to carry phosphorylcholine, PC, the pro-inflammatory target for PC-mAb.

Read more »
Media no image

Athera allowed US composition of matter patents for therapeutic antibodies

Press Releases   •   Sep 25, 2017 09:00 CEST

Stockholm Sept 25, 2017 

Athera Biotechnologies AB today announced that two composition of matter patents have been allowed for antibodies with binding to phosphorylcholine, PC. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies covered by the patents are designed to target and block PC and thereby reduce inflammation.

“Our lead candidate PC-mAb is covered by these patents and we are thrilled with the progress of the project through early clinical development and towards the upcoming Phase 2a study” says Carina Schmidt, CEO of Athera.

The clinical stage fully human antibody PC-mAb from Athera is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications in immunovascular diseases.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB

Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Athera announce that two patents have been allowed for antibodies with binding to phosphorylcholine, PC. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies covered by the patents, including the lead candidate from Athera, PC-mAb, are designed to target and block PC and thereby reduce inflammation.

Read more »
Media no image

Athera concludes follow-up visits in multiple dosing trial with its immunovascular antibody

Press Releases   •   Sep 19, 2017 09:00 CEST

Stockholm Sept 19, 2017 

Athera Biotechnologies AB today announced that all follow-up visits (12 weeks after last dosing) in a multiple dosing study in healthy volunteers with its fully human antibody PC-mAb have been completed. Positive preliminary safety and pharmacokinetics data provides continued support for further clinical development with once monthly administrations.

“We are very happy with the preliminary data of this study which supports our development plans and the upcoming initiation of the Phase 2a study”, says Carina Schmidt, CEO of Athera.

The fully human PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC, and act to support the immune response to vascular inflammation challenges, and thereby reduce the risk for complications.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Athera today announced that all follow-up visits (12 weeks after last dosing) in a multiple dosing study in healthy volunteers with its fully human antibody PC-mAb have been completed. Positive preliminary safety and pharmacokinetics data provides continued support for further clinical development plans.

Read more »
Media no image

Athera completes financing to advance clinic with immunovascular antibody

Press Releases   •   Aug 29, 2017 09:30 CEST

Stockholm August 29, 2017

Athera Biotechnologies AB has completed a 57 million SEK financing from current major owners; The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc AB, together with new investor Ribbskottet AB, an investment company lead by Anders Bladh. Mr Bladh has a long background from international asset management, finance and banking as well as real estate. Additional investors include Athera´s management team and Antaros Medical AB.

The 57 million SEK will be used to fully finance the next steps in clinical development of Athera’s lead project PC-mAb, currently preparing for start of clinical Phase 2. PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications.

“This marks the start of a game-changing period for Athera, securing the necessary funding for the next Phase 2 study with our fully human antibody PC-mAb,”, says Athera CEO Carina Schmidt. “The new ownership will further strengthen our team and support the development of this exciting compound in a market with high medical need.”

For more information contact:

Carina Schmidt, CEO, Athera Biotechnologies AB
Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB. For more information: www.athera.se

Athera Biotechnologies AB has completed a 57 million SEK financing from current major owners, together with new investor Ribbskottet AB. The investment will be used to fully finance the next steps in clinical development of Athera’s lead project PC-mAb, currently preparing for start of clinical Phase 2.

Read more »
Media no image

Athera Receives FDA Orphan Drug Designation for PC-mAb in prevention of vascular access failure in kidney disease patients

Press Releases   •   Jun 21, 2017 15:00 CEST

Athera Biotechnologies AB announced today that the the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to the fully human antibody PC-mAb, for the treatment of patients with end stage renal disease, who are preparing for or undergo hemodialysis, to prevent vascular access failure.

“We are pleased that the FDA have granted orphan drug designation to our therapeutic candidate PC-mAb.” says Carina Schmidt, CEO of Athera. “The granting highlights the great unmet medical need for new therapies for kidney disease patients, who are dependent on a well-functioning vascular access for their hemodialysis.”

End stage renal disease (ESRD) patients have a loss of kidney function and require either dialysis or a kidney transplant to survive. All patients on hemodialysis require a reliable vascular access. It has been estimated that 20% of all hospitalizations in the hemodialysis population are due to vascular access dysfunction. Creation of a well-functioning vascular access is a main concern, as complications substantially contribute to morbidity and mortality. PC-mAb reduces inflammation by targeting PC (phosphorylcholine), and therefore has the potential to prevent the neointimal hyperplasia that is the root cause of vascular access failure. The fully human PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. In addition, Athera has developed a biomarker and companion diagnostics product, CVDefine® kit. The biomarker could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Development of PC-mAb is co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Athera announced today that FDA have granted Orphan Drug Designation to the fully human antibody PC-mAb for the treatment of patients with end stage renal disease, who are preparing for or undergo hemodialysis, to prevent vascular access failure. PC-mAb is designed to mimic endogenous antibodies to PC and act to support the immune response to vascular inflammation and thereby reduce complications.

Read more »
Media no image

Athera completes multiple dosing trial with its fully human antibody PC-mAb

Press Releases   •   Jun 20, 2017 12:12 CEST

Athera Biotechnologies AB today announced that last dosing in a multiple dosing study in healthy volunteers has been given with its fully human antibody PC-mAb, with continued support for development based on preliminary safety and pharmacokinetics reporting.

“We are very pleased with the progress of this MAD study and that the preliminary data support our plans with once monthly administration over longer time. We are looking forward to the complete results after the follow-up visits” says Carina Schmidt, CEO of Athera. “The study is a preparation for the Phase 2a study that we are planning to submit in the next month.”

The fully human PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. In addition, Athera has developed a biomarker and companion diagnostics product, CVDefine® kit. The biomarker could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

The Swedish biotech company Athera Biotechnologies AB announced that last dosing in a multiple dosing study in healthy volunteers has been given with its fully human antibody PC-mAb, with continued support for development based on preliminary safety and pharmacokinetics reporting. The study is a preparation for the Phase 2a study that is planned for submission in the next month.

Read more »
Media no image

Proteomics used to investigate effects on inflammation response following vascular surgery and treatment with the immunovascular antibody PC-mAb

Press Releases   •   May 12, 2017 12:00 CEST

Scientists report a proteomic study of systemic inflammation following vascular surgery and treatment with the fully human antibody PC-mAb from Athera at the recent 19th Swedish Cardiovascular Spring meeting. The group of scientists, from Örebro University, Karolinska Institutet and the biotech company Athera, concluded that proteomics can be used to study treatment effects in future studies. The fully human antibody PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications.

Revascularization in the legs in patients with severe peripheral arterial disease, PAD, is done to restore blood flow, to reduce pain and restore mobility. However, the risk for amputation of the affected limb is still high, as well as severe events like heart attack and stroke. Open surgery is well known to cause an acute inflammatory reaction lasting for days and weeks, and patients suffer an increased risk for complications during this period, but it is still largely unknown how the surgery affects inflammation mediators. Proteomic analysis in longitudinal samples can give such information, knowledge that could improve risk management in the sub-acute phase following surgery. The patients were participating in a safety study of PC-mAb, a novel fully human therapeutic antibody targeting phosphorylcholine (PC), a key mediator of vascular inflammation. Blood samples were obtained before and at several time points after surgery. A novel multiplex proteomics assay from OLINK was used to determine levels of 251 proteins. As expected, established markers for the acute phase reaction (IL-6 and CRP) were markedly elevated after surgery. Moreover, 65 of 251 proteins measured were significantly increased from baseline to the days after surgery. Only 3 proteins were significantly reduced in the acute phase following surgery and 18 proteins were differentially affected by treatment with PC-mAb. The results are promising and support the use of proteomics analysis to be used to study treatment effects of PC-mAb in future clinical studies.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. In addition, Athera has developed a biomarker and companion diagnostics product, CVDefine® kit. The biomarker could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Scientists report a proteomic study of systemic inflammation following vascular surgery and treatment with the fully human antibody PC-mAb from Athera. PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies and act to support the immune response to vascular inflammation challenges.

Read more »
Media no image

Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS

Press Releases   •   Sep 28, 2016 15:00 CEST

Copenhagen September 28, 2016 Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against immunovascular diseases, presents data from the first study in patients with peripheral artery disease (PAD) at the annual meeting of ESVS (European Society of Vascular Surgeons) in Copenhagen. Conclusions from this Phase 1b study in PAD patients were positive, showing good safety and tolerability, as well as antibody properties supporting once monthly dosing also in patients. The study, run at Karolinska University Hospital in Stockholm, included 12 patients receiving a single dose of Athera’s lead candidate PC-mAb or placebo.

Professor Gunnar Olsson, Chairman of the Board, said “The study data confirms that there are generally low levels of endogenous antibodies to phosphorylcholine, anti-PC, in PAD patients, indicating a window for reconstitution therapy with PC-mAb. We also noted that PAD patients have markedly reduced limb arterial dynamic functionality, which was an important observation for future clinical study designs. This really give a good base for succinct definitions of clinically relevant endpoints in the planned phase 2a study in this patient group.”

“We are very pleased to have reached this important milestone and to be able to report safety data supporting next development steps, efficacy trials with PC-mAb, said Athera CEO Carina Schmidt. “We think PC-mAb has significant potential to address unmet medical needs in PAD, but also in other immunovascular diseases, and this should represent a significant value for an industrial partner.”

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email:c.schmidt@athera.se

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. In addition, Athera has developed a biomarker and companion diagnostics product, CVDefine® kit. The biomarker could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. PC-mAb provides an opportunity to address the need for improved secondary prevention after revascularization in severe PAD patients and reduce the associated risks for complications and new vascular disease events. PAD is a chronic disease that severely restricts the mobility of the patients and therefore their quality of life. It affects about 5% in ages 45-50 and 19% in ages 85-90. With severe PAD the disease is causing extensive pain also at rest, leading to further morbidity. The risk for severe events like heart attack and stroke is high, as well as the risk for amputation of the affected limbs. Development of PC-mAb is co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se

Athera, a biotech company focused on developing a new antibody against immunovascular diseases, presents data from the first study in patients with peripheral artery disease (PAD) at the annual meeting of ESVS. Conclusions from this Phase 1b study in PAD patients were positive, showing good safety and tolerability, as well as antibody properties supporting once monthly dosing also in patients.

Read more »
Media no image

Athera Biotechnologies completes 24 million SEK financing

Press Releases   •   Dec 03, 2015 08:04 CET

Stockholm December 3, 2015 Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Additional investors in the consortium are Athera´s Board and management, as well as other investors, including Antaros Medical AB. Dr. Jonas Brambeck, Investment Manager at Industrifonden, will join the Board of Directors.

The 24 million SEK will be used to finance further clinical development of Athera’s lead project PC-mAb, currently in clinical Phase I studies, to become a Phase 2-ready project. PC-mAb provides an opportunity to address the need for improved secondary prevention after revascularization in severe peripheral artery disease (PAD) patients and reduce the associated risks for complications and new cardiovascular disease (CVD) events.

“This marks the beginning of an exciting period for Athera, securing the necessary funding for completing the Phase 1 study in patients and prepare for Phase 2 studies with our fully human antibody PC-mAb,”, said Athera CEO Carina Schmidt. “The new ownership structure will give us access to an excellent platform of experience and capacities that will facilitate our preparations to secure an industrial partner for late clinical development and commercialization.”

Dr Gunnar Olsson, Chairman of the Board, said “Athera´s candidate drug has significant potential to address unmet medical needs in cardiovascular disease. Prevention of complications in patients with severe PAD represents an important niche market and PC-mAb has great opportunities to contribute to better treatment for these patients.”

“We are very pleased with this investment in Athera,” said Mattias Klintemar, Director of Investments for Östersjöstiftelsen “We were an early investor in this interesting company with a unique and promising cardiovascular drug candidate in early clinical development. We are now looking forward to continue our support in the company to achieve its clinical and commercial milestones during the coming years.”

For more information contact:
Jonas Brambeck, Investment Manager, Industrifonden
Phone: +46 (0) 708 791 937 , email: Jonas.brambeck@industrifonden.se

Carina Schmidt, CEO, Athera Biotechnologies AB
Phone: +46 (0)76 1938 190, email:c.schmidt@athera.se

Mattias Klintemar, Director of Investments, Östersjöstiftelsen

Phone: +46 (0)70 932 64 67, email: mattias.klintemar@ostersjostiftelsen.se 

About Athera Biotechnologies AB

The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease (CVD). Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. In addition, Athera has developed a biomarker and companion diagnostics product, CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for CVD and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics. Development of PC-mAb is co-funded by EU FP7 in the CARDIMMUN project that was started in 2013. For more information: www.athera.se

About Industrifonden

Industrifonden is one of Sweden's most experienced and active investors in early-stage tech and life science companies aiming for international growth. We are a long-term partner with about SEK 4 billion in assets and serve as an active owner together with entrepreneurs and co-investors. Our passion is to build lasting value and successful companies. For further information, visit www.industrifonden.com or twitter.com/industrifonden

About The Foundation for Baltic and East European Studies (Östersjöstiftelsen)

Östersjöstiftelsen (the Foundation for Baltic and East European Studies) was founded by the Swedish government in 1994 to support research, doctoral studies and academic infrastructure at Södertörn University. Östersjöstiftelsen has funded approximately 200 research projects and the education of 140 doctoral students at Södertörn University. From 2000 to 2015, Södertörn University has been granted funds totalling SEK 3 billion. In October 2015, the Foundation managed assets totaling over SEK 5 billion.

About Linc Invest AB

Linc invest AB invests in Life Science companies. The main investments are in Pharmalink, MedCap, Stille, Arcoma, SweVet, Bringwell and Boule. For further information, contact Bengt Julander +46 70 319 5909, bengt.julander@linc.se

About Antaros Medical AB

Antaros Medical AB is a Swedish company pioneering new frontiers in innovative MRI & PET imaging techniques in clinical drug development to improve understanding of human pathophysiology. We enable decision makers to optimize outcomes and minimize risk. Our current customers include both small and big pharma companies. For more information: www.antarosmedical.com

Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Additional investors are Athera´s Board and management, as well as other investors.

Read more »

Images & Videos 3 images

Contacts 3 contacts

  • Press Contact
  • Chief Executive Officer, M.Sc.
  • Chief Executive Officer, M.Sc.
  • c.schmidt@athera.se
  • +46 (0)76-1938190
Carina Schmidt has nearly 30 years industrial experience, mainly in business... Show more

About Athera Biotechnologies AB

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease

Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of immunovascular disease. The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Athera is managed by a core team of senior professionals from the pharmaceutical and diagnostics industries in a semi-virtual organization.

Address

  • Athera Biotechnologies AB
  • Sankt Eriksgatan 117, 4th floor
  • 11343 Stockholm
  • Sweden
  • Our homepage